Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: Antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity

Pharmaceutical Research

Volumn 31, Issue 5, 2014, Pages 1290-1301

  Marquez, Béatrice ^a,b   Pourcelle, Vincent ^a   Vallet, Coralie M ^a   Mingeot Leclercq, Marie Paule ^a   Tulkens, Paul M ^a   Marchand Bruynaert, Jacqueline ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b EUROPEAN COMMISSION   (Belgium)

Author keywords

antibacterial activity; drug accumulation; fluoroquinolones; lipophilicity; Mrp4

Indexed keywords

CIPROFLOXACIN; GEMFIBROZIL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; N ACETYL CIPROFLOXACIN; N BENZOYL CIPROFLOXACIN; N BENZYL CIPROFLOXACIN; N ETHYL CIPROFLOXACIN; QUINOLONE DERIVATIVE; RESERPINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CELLULAR DISTRIBUTION; DRUG ACCUMULATION; DRUG SYNTHESIS; ESCHERICHIA COLI; LISTERIA MONOCYTOGENES; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; ANIMAL; CELL FRACTIONATION; CELL LINE; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CIPROFLOXACIN; ESCHERICHIA COLI; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; SUBCELLULAR FRACTIONS;

EID: 84902256486     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1250-x     Document Type: Article

References (46)

1. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect. 2005;11(4):256-80.
2. Michot JM, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob Agents Chemother. 2004;48(7):2673-82.
3. Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother. 2003;51(5):1167-73.
4. Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets. 2011;12(5):600-20.
5. Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G. Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008;97(9):3483-93.
6. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006;34(4):690-5.
7. Marquez B, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother. 2009;53(6):2410-6.
8. Marquez B, Ameye G, Vallet CM, Tulkens PM, Poirel HA, Van Bambeke F. Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin. PLoS One. 2011;6(12):e28368.
9. Haslam IS, Wright JA, O'Reilly DA, Sherlock DJ, Coleman T, Simmons NL. Intestinal ciprofloxacin efflux; the role of breast cancer resistance protein, BCRP (ABCG2). Drug Metab Dispos. 2011;39(12):2321-8.
10. Michot JM, Heremans MF, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob Agents Chemother. 2006;50(5):1689-95.
11. Lismond A, Tulkens PM, Mingeot-Leclercq MP, Courvalin P, Van Bambeke F. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin. Antimicrob Agents Chemother. 2008;52(9):3040-6.
12. Vallet CM, Marquez B, Nhiri N, Anantharajah A, Mingeot-Leclercq MP, Tulkens PM, et al. Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. Toxicology. 2011;290(2-3):178-86.
13. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother. 2000;44(3):798-801.
14. Letafat B, Emami S, Mohammadhosseini N, Faramarzi MA, Samadi N, Shafiee A, et al. Synthesis and antibacterial activity of new N-[2-(thiophen-3-yl)ethyl] piperazinyl quinolones. Chem Pharm Bull (Tokyo). 2007;55(6):894-8.
15. Pieroni M, Dimovska M, Brincat JP, Sabatini S, Carosati E, Massari S, et al. From 6-aminoquinolone antibacterials to 6-amino-7- thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps. J Med Chem. 2010;53(11):4466-80.
16. Martinez M, McDermott P, Walker R. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet J. 2006;172(1):10-28.
17. Cormier R, Burda WN, Harrington L, Edlinger J, Kodigepalli KM, Thomas J, et al. Studies on the antimicrobial properties of N-acylated ciprofloxacins. Bioorg Med Chem Lett. 2012;22(20):6513-20.
18. Wang S, Jia XD, Liu ML, Lu Y, Guo HY. Synthesis, antimycobacterial and antibacterial activity of ciprofloxacin derivatives containing a N-substituted benzyl moiety. Bioorg Med Chem Lett. 2012;22(18):5971-5.
19. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(2):649-58.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 2012;22th informational supplement (MS100-S22).
21. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003;47(7):2283-92.
22. Al Dgither S, Alvi SN, Hammami MM. Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma. J Pharm Biomed Anal. 2006;41(1):251-5.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-75.
24. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother. 2005;49(6):2429-37.
25. Vassault A. Lactate dehydrogenase. In: Bergemeyer HU, editors. Methods in enzymatic analysis. VHC Publishers, Veinheim, Federal Republic of Germany; 1987. p. 118-126.
26. Renard C, Vanderhaeghe HJ, Claes PJ, Zenebergh A, Tulkens PM. Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. Antimicrob Agents Chemother. 1987;31(3):410-6.
27. Aubert-Tulkens G, Van Hoof F, Tulkens P. Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study. Lab Invest. 1979;40(4):481-91.
28. Petersen U, Grohe K, Kuehle E, Zeiler H-J, Metzger KG. Quinolonecarboxylic acids and antibacterial agents containing these compounds. 17-12-1985;US19840576595 19840203.
29. Montero MT, Freixas J, Hernandez-Borrell J. Expression of the partition coefficients of a homologous series of 6-fluoroquinolones. Int J Pharm. 1997;149(2):161-70.
30. Kerns EH, Di L. Lipophilicity methods. In: Kerns EH, Di L, editors. Drug-like properties: concepts, structure design and methods. San Diego, CA: Academic Press, Elsevier; 2008. p. 260-70.
31. Alovero F, Nieto M, Mazzieri MR, Then R, Manzo RH. Mode of action of sulfanilyl fluoroquinolones. Antimicrob Agents Chemother. 1998;42(6):1495-8.
32. Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1996;40(8):1835-42.
33. Piddock LJ, Jin YF, Griggs DJ. Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J Antimicrob Chemother. 2001;47(3):261-70.
34. Godreuil S, Galimand M, Gerbaud G, Jacquet C, Courvalin P. Efflux pump Lde is associated with fluoroquinolone resistance in Listeria monocytogenes. Antimicrob Agents Chemother. 2003;47(2):704-8.
35. Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother. 1993;37(1):128-9.
36. Nikaido H, Pages JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev. 2011;36(2):340-63.
37. Vallet CM, Marquez B, Ngabirano E, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, et al. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. Int J Antimicrob Agents. 2011;38(3):249-56.
38. Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother. 1993;37(7):1393-9.
39. Yu X, Zipp GL, Davidson III GW. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharm Res. 1994;11(4):522-7.
40. Vazquez JL, Berlanga M, Merino S, Domenech O, Vinas M, Montero MT, et al. Determination by fluorimetric titration of the ionization constants of ciprofloxacin in solution and in the presence of liposomes. Photochem Photobiol. 2001;73(1):14-9.
41. Lizondo M, Pons M, Gallardo M, Estelrich J. Physicochemical properties of enrofloxacin. J Pharm Biomed Anal. 1997;15(12):1845-9.
42. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci. 1989;29(3):163-72.
43. Klopman G, Li JY, Wang S, Dimayuga M. Computer automated log P calculations based on an extended group contribution approach. J Chem Inf Comput Sci. 1994;34(4):752-81.
44. Ba BB, Arpin C, Vidaillac C, Chausse A, Saux MC, Quentin C. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. Antimicrob Agents Chemother. 2006;50(6):1931-6.
45. Ghisalberti D, Masi M, Pages JM, Chevalier J. Chloramphenicol and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem Biophys Res Commun. 2005;328(4):1113-8.
46. Furet YX, Deshusses J, Pechere JC. Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 1992;36(11):2506-11.